| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Lomedeucitinib selectively targets Tyrosine Protein Kinase 2 (TYK2), a member of the Janus kinase (JAK) family and a non-receptor tyrosine kinase. TYK2 plays a critical role in mediating cytokine signaling pathways involved in inflammation and immune responses, particularly downstream of interleukins IL-12 and IL-23. By binding to and inhibiting TYK2, Lomedeucitinib disrupts the JAK-STAT signaling cascade, which is a recognized driver in systemic and autoimmune immune disorders. This selective TYK2 inhibition is the primary mechanism through which the compound exerts its anti-inflammatory effects.
|
|---|---|
| ln Vitro |
In in vitro studies, Lomedeucitinib demonstrates significant anti-inflammatory activity by potently inhibiting the production of interferon-alpha (IFNalpha) downstream of the IL-12/TYK2 signaling pathway. The compound exhibits a potent inhibitory effect with an IC50 value of 0.047 microM for IFNalpha production. This inhibition of IFNalpha, a key pro-inflammatory cytokine, underlies its therapeutic potential for treating inflammatory conditions such as plaque psoriasis. The in vitro potency data supports the compound's mechanism of action as a selective TYK2 inhibitor that effectively blocks downstream inflammatory cytokine production at low micromolar concentrations.
|
| ln Vivo |
In vivo data for Lomedeucitinib specifically are limited in publicly available literature. However, as an orally administered small molecule TYK2 inhibitor, it is expected to exert systemic anti-inflammatory effects by inhibiting TYK2-dependent cytokine signaling pathways. The compound has been administered orally in clinical trials involving healthy volunteers (Phase 1) and patients with moderate-to-severe psoriasis (Phase 2), indicating established in vivo tolerability and exposure. The completed Phase 2 trial NCT05730725 assessed effectiveness and safety in psoriasis participants, suggesting that the compound achieves sufficient systemic exposure to modulate inflammatory responses and produce therapeutic effects in the skin.
|
| Enzyme Assay |
The typical in vitro enzyme or receptor binding assay for TYK2 inhibitors such as Lomedeucitinib involves measuring the compound's ability to inhibit the kinase activity of recombinant TYK2 enzyme. A generic protocol: recombinant TYK2 enzyme is incubated with varying concentrations of the test compound (e.g., 0.001-10 microM) in kinase reaction buffer containing ATP and a peptide substrate. After incubation at room temperature for 1-2 hours, the reaction is terminated, and the amount of phosphorylated substrate is quantified using methods such as HTRF (Homogeneous Time-Resolved Fluorescence) or ELISA. IC50 values are calculated by fitting inhibition curves. For Lomedeucitinib, specific experiments showed significant inhibition of IFNalpha production downstream of IL-12/TYK2, indicating effective TYK2 pathway blockade.
|
| Cell Assay |
The in vitro cellular assay for Lomedeucitinib typically measures inhibition of cytokine-induced signaling in cell lines or primary cells. A representative protocol: cells (such as human peripheral blood mononuclear cells or reporter cell lines) are pre-incubated with various concentrations of Lomedeucitinib for 1-2 hours, then stimulated with IL-12 to activate the TYK2-dependent pathway. After overnight incubation (16-24 hours), supernatant is collected, and IFNalpha levels are measured by ELISA. The compound's activity is calculated as the percentage inhibition of IFNalpha production compared to vehicle control. For Lomedeucitinib, this assay yielded an IC50 value of 0.047 microM for IFNalpha inhibition, demonstrating potent cellular activity against TYK2-mediated signaling.
|
| Animal Protocol |
The in vivo protocol for evaluating TYK2 inhibitors like Lomedeucitinib in animal models typically involves oral administration in rodent models of inflammatory disease. A generic protocol: animals (e.g., mouse model of psoriasis induced by imiquimod) are randomized into groups (vehicle control, positive control, and test compound groups). Lomedeucitinib is administered orally once or twice daily at doses such as 1, 3, or 10 mg/kg for 7-14 days. Disease severity is assessed daily using clinical scores (erythema, scaling, thickness). At study termination, skin samples and blood are collected for histopathological analysis, measurement of inflammatory cytokines (e.g., IFNalpha, IL-12, IL-23), and compound concentration analysis. This protocol assesses both efficacy and target engagement in vivo.
|
| ADME/Pharmacokinetics |
Based on data for TYK2 inhibitors as a class, Lomedeucitinib is orally administered and likely exhibits good oral bioavailability. It is metabolized primarily by liver enzymes, which may involve oxidation or conjugation reactions leading to various metabolites. The compound demonstrates stability under standard storage conditions, with recommended storage at -20degC in powder form for up to 3 years and in solution at -80degC for up to 1 year. In vivo, TYK2 inhibitors generally achieve peak plasma concentrations within 1-4 hours post-oral administration and have half-lives ranging from 4 to 12 hours in preclinical species, though specific PK parameters for Lomedeucitinib from published literature are not publicly available.
|
| Toxicity/Toxicokinetics |
The safety and toxicity profile of Lomedeucitinib has been evaluated in clinical trials. According to safety data from supplier documentation, the compound is classified as toxic, containing a pharmaceutically active ingredient. Hazard statements indicate that it may be very toxic if swallowed (R28), irritating to skin (R38), with risk of serious damage to eyes (R41), and toxic with danger of serious damage to health by prolonged exposure (R48). Lomedeucitinib has undergone Phase 1 clinical trials in healthy volunteers (NCT05546151, NCT04175925) to assess safety and tolerability, including in healthy participants of Japanese descent. The completion of these trials without reported serious adverse events suggests an acceptable safety profile for further clinical development.
|
| References | |
| Additional Infomation |
Lomedeucitinib (BMS-986322) is an investigational drug under development by Bristol-Myers Squibb for the treatment of plaque psoriasis and psoriatic arthritis. It has completed Phase 1 trials in healthy volunteers and Phase 2 trials for moderate-to-severe psoriasis (NCT05730725). The drug is administered orally and acts by selectively targeting TYK2. This TYK2 inhibitor is one of several JAK inhibitors being developed for autoimmune diseases. The usage of the INN stem "-citinib" indicates its classification as a Janus kinase inhibitor. The compound's maximum clinical trial phase is Phase II, with one investigational indication in psoriasis. No information about regulatory approval (NDA or marketing authorization) is currently available, as Lomedeucitinib remains in the research and clinical development stage.
|
| Molecular Formula |
C18H17D3N6O4S
|
|---|---|
| Molecular Weight |
419.47
|
| Exact Mass |
419.146
|
| CAS # |
2328064-33-9
|
| Related CAS # |
Lomedeucitinib; 2328068-29-5; (S)-Lomedeucitinib
|
| PubChem CID |
152206488
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
765
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=C(C=CC=N2)S(=O)(=O)C)NC(=O)C3CC34CC4
|
| InChi Key |
VWIVBQZLVAGLMH-FIBGUPNXSA-N
|
| InChi Code |
InChI=1S/C18H20N6O4S/c1-19-17(26)14-11(21-15-12(29(2,27)28)4-3-7-20-15)8-13(23-24-14)22-16(25)10-9-18(10)5-6-18/h3-4,7-8,10H,5-6,9H2,1-2H3,(H,19,26)(H2,20,21,22,23,25)/i1D3
|
| Chemical Name |
4-[(3-methylsulfonyl-2-pyridinyl)amino]-6-(spiro[2.2]pentane-2-carbonylamino)-N-(trideuteriomethyl)pyridazine-3-carboxamide
|
| Synonyms |
(rac)-BMS-986322
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~59.60 mM; with ultrasonication (<60°C))
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3840 mL | 11.9198 mL | 23.8396 mL | |
| 5 mM | 0.4768 mL | 2.3840 mL | 4.7679 mL | |
| 10 mM | 0.2384 mL | 1.1920 mL | 2.3840 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
